Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs McDonald's Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while McDonald's Corp trades at $240 (market cap $166.87B). The key difference: McDonald's Corp is far larger — about 18.8× Kymera Therapeutics Inc. Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and McDonald's Corp for 165 Days on average.
| KYMR | MCD | |
|---|---|---|
Market Cap | $8.87B | $166.87B |
Volume | 779,107 | 4,543,119 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $341.06 |
52-Week Low | $55.80 | $230.88 |
Typical Hold Time | 0 Days | 165 Days |
Enterprise Value | $8.26B | $220.64B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
McDonald's (MCD) trades at $235.81, up 0.07% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth is steady, reaching $26.89B in 2025, while net income margin remains robust at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and menu innovation to drive growth.
The outlook is supported by analyst optimism with a consensus price target of $284.70, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42B. The stock presents a value opportunity with a P/E of 19.16, but investors should weigh execution risks against growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
